Michael S. Kinch - Publications

1993-1996 Basic Medical Sciences Purdue University, West Lafayette, IN, United States 
 2001-2006 Cancer Biology MedImmune, Inc 
 2006-2011 Research and Development Functional Genetics 
 2011-2014 Yale Center for Molecular Discovery Yale University, New Haven, CT 
 2014- Biochemistry and Molecular Biophysics Washington University, Saint Louis, St. Louis, MO 
cell biology, immunology

114 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Kinch MS, Kraft Z, Schwartz T. Sources of innovation for new medicines: questions of sustainability. Drug Discovery Today. PMID 33144150 DOI: 10.1016/j.drudis.2020.10.026  1
2020 Kinch MS. Oh, the Frustration of Antibodies! Acs Pharmacology & Translational Science. 3: 1035-1036. PMID 33073201 DOI: 10.1021/acsptsci.0c00138  0.01
2020 Kinch MS, Kraft Z, Schwartz T. 2019 in review: FDA approvals of new medicines. Drug Discovery Today. PMID 32927064 DOI: 10.1016/J.Drudis.2020.09.002  1
2020 Kinch MS, Horn C, Kraft Z, Schwartz T. Expanding roles for academic entrepreneurship in drug discovery. Drug Discovery Today. PMID 32920058 DOI: 10.1016/J.Drudis.2020.09.004  1
2019 Griesenauer RH, Schillebeeckx C, Kinch MS. CDEK: Clinical Drug Experience Knowledgebase. Database : the Journal of Biological Databases and Curation. 2019. PMID 31411687 DOI: 10.1093/Database/Baz087  1
2019 Kinch MS, Griesenauer RH. 2018 in review: FDA approvals of new molecular entities. Drug Discovery Today. PMID 31158510 DOI: 10.1016/J.Drudis.2019.05.022  1
2019 Griesenauer RH, Schillebeeckx C, Kinch MS. Assessing the public landscape of clinical-stage pharmaceuticals through freely available online databases. Drug Discovery Today. PMID 30690196 DOI: 10.1016/J.Drudis.2019.01.010  1
2018 Kinch MS, Kinch GA, Griesenauer RH. Lost medicines: a longer view of the pharmaceutical industry with the potential to reinvigorate discovery. Drug Discovery Today. PMID 30223039 DOI: 10.1016/J.Drudis.2018.09.006  1
2018 Kinch MS, Griesenauer RH. 2017 in review: FDA approvals of new molecular entities. Drug Discovery Today. PMID 29751111 DOI: 10.1016/J.Drudis.2018.05.011  1
2017 Griesenauer RH, Moore R, Kinch MS. NIH Support for FDA-Approved Medicines. Cell Chemical Biology. 24: 1315-1316. PMID 29149588 DOI: 10.1016/J.Chembiol.2017.11.002  1
2017 Griesenauer RH, Kinch MS. An overview of FDA-approved vaccines & their innovators. Expert Review of Vaccines. PMID 28931331 DOI: 10.1080/14760584.2017.1383159  1
2017 Griesenauer RH, Kinch MS. 2016 in review: FDA approvals of new molecular entities. Drug Discovery Today. PMID 28687460 DOI: 10.1016/J.Drudis.2017.06.011  1
2017 Kinch MS, Woodard P. Analysis of FDA-approved imaging agents. Drug Discovery Today. PMID 28341604 DOI: 10.1016/J.Drudis.2017.03.006  0.01
2016 Kinch MS, Moore R. Innovator Organizations in New Drug Development: Assessing the Sustainability of the Biopharmaceutical Industry. Cell Chemical Biology. 23: 644-53. PMID 27341432 DOI: 10.1016/J.Chembiol.2016.05.013  1
2016 Kinch MS. 2015 in review: FDA approval of new drugs. Drug Discovery Today. PMID 27109618 DOI: 10.1016/J.Drudis.2016.04.008  1
2016 Patridge E, Gareiss P, Kinch MS, Hoyer D. An analysis of FDA-approved drugs: natural products and their derivatives. Drug Discovery Today. 21: 204-7. PMID 25617672 DOI: 10.1016/J.Drudis.2015.01.009  1
2016 Kinch MS, Surovtseva Y, Hoyer D. An analysis of FDA-approved drugs for cardiovascular diseases. Drug Discovery Today. 21: 1-4. PMID 25218930 DOI: 10.1016/J.Drudis.2014.09.001  1
2015 Patridge EV, Gareiss PC, Kinch MS, Hoyer DW. An analysis of original research contributions toward FDA-approved drugs. Drug Discovery Today. 20: 1182-7. PMID 26113307 DOI: 10.1016/J.Drudis.2015.06.006  1
2015 Kinch MS. 2014 in review: FDA approval of new drugs. Drug Discovery Today. PMID 26100738 DOI: 10.1016/J.Drudis.2015.06.004  1
2015 Kinch MS, Hoyer D. A history of drug development in four acts. Drug Discovery Today. 20: 1163-8. PMID 25908577 DOI: 10.1016/J.Drudis.2015.04.003  1
2015 Kinch MS, Merkel J. An analysis of FDA-approved drugs for inflammation and autoimmune diseases. Drug Discovery Today. 20: 920-3. PMID 25701283 DOI: 10.1016/J.Drudis.2015.02.006  1
2015 Kinch MS. An analysis of FDA-approved drugs for neurological disorders. Drug Discovery Today. 20: 1040-3. PMID 25681791 DOI: 10.1016/J.Drudis.2015.02.003  1
2015 Kinch MS, Umlauf S, Plummer M. An analysis of FDA-approved drugs for metabolic diseases. Drug Discovery Today. 20: 648-51. PMID 25680688 DOI: 10.1016/J.Drudis.2015.02.002  1
2015 Kinch MS, Flath R. New drug discovery: extraordinary opportunities in an uncertain time. Drug Discovery Today. 20: 1288-92. PMID 25528676 DOI: 10.1016/J.Drudis.2014.12.008  1
2015 Kinch MS, Raffo J. Sources of innovation: an assessment of intellectual property. Drug Discovery Today. 20: 500-4. PMID 25499663 DOI: 10.1016/J.Drudis.2014.12.002  1
2015 Kinch MS, Hoyer D, Patridge E, Plummer M. Target selection for FDA-approved medicines. Drug Discovery Today. 20: 784-9. PMID 25462532 DOI: 10.1016/J.Drudis.2014.11.001  1
2015 Kinch MS. Post-approval fate of pharmaceutical companies. Drug Discovery Today. 20: 170-4. PMID 25448760 DOI: 10.1016/J.Drudis.2014.10.013  1
2015 Kinch MS. An overview of FDA-approved biologics medicines. Drug Discovery Today. 20: 393-8. PMID 25220442 DOI: 10.1016/J.Drudis.2014.09.003  1
2015 Kinch MS. An analysis of FDA-approved drugs for pain and anesthesia. Drug Discovery Today. 20: 3-6. PMID 25218931 DOI: 10.1016/J.Drudis.2014.09.002  1
2015 Kinch MS, Patridge E. An analysis of FDA-approved drugs for psychiatric disorders. Drug Discovery Today. 20: 292-5. PMID 25200172 DOI: 10.1016/J.Drudis.2014.08.013  1
2014 Kinch MS. An analysis of FDA-approved drugs for oncology. Drug Discovery Today. 19: 1831-5. PMID 25172803 DOI: 10.1016/J.Drudis.2014.08.007  1
2014 Kinch MS, Patridge E, Plummer M, Hoyer D. An analysis of FDA-approved drugs for infectious disease: antibacterial agents. Drug Discovery Today. 19: 1283-7. PMID 25043770 DOI: 10.1016/J.Drudis.2014.07.005  1
2014 Kinch MS, Merkel J, Umlauf S. Trends in pharmaceutical targeting of clinical indications: 1930-2013. Drug Discovery Today. 19: 1682-5. PMID 24881779 DOI: 10.1016/J.Drudis.2014.05.021  1
2014 Kinch MS, Patridge E. An analysis of FDA-approved drugs for infectious disease: HIV/AIDS drugs. Drug Discovery Today. 19: 1510-3. PMID 24880109 DOI: 10.1016/J.Drudis.2014.05.012  1
2014 Kinch MS. The rise (and decline?) of biotechnology. Drug Discovery Today. 19: 1686-90. PMID 24747562 DOI: 10.1016/J.Drudis.2014.04.006  1
2014 Kinch MS, Haynesworth A, Kinch SL, Hoyer D. An overview of FDA-approved new molecular entities: 1827-2013. Drug Discovery Today. 19: 1033-9. PMID 24680947 DOI: 10.1016/J.Drudis.2014.03.018  1
2011 Gökmen-Polar Y, Toroni RA, Hocevar BA, Badve S, Zhao Q, Shen C, Bruckheimer E, Kinch MS, Miller KD. Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer. Breast Cancer Research and Treatment. 127: 375-84. PMID 20602165 DOI: 10.1007/S10549-010-1004-Y  1
2010 Diaz L, Mao H, Zhou Y, Kohli M, Cassella J, Santos D, Fesseha Z, Weng K, Chen H, Bamba D, Marks JD, Goldblatt M, Kinch M. TSG101 exposure on the surface of HIV-1 infected cells: implications for monoclonal antibody therapy for HIV/AIDS. American Journal of Translational Research. 2: 368-80. PMID 20733947  1
2010 Reiske H, Sui B, Ung-Medoff H, Donahue R, Li WB, Goldblatt M, Li L, Kinch MS. Identification of annexin A13 as a regulator of chemotherapy resistance using random homozygous gene perturbation. Analytical and Quantitative Cytology and Histology / the International Academy of Cytology [and] American Society of Cytology. 32: 61-9. PMID 20701074  1
2010 Warren TK, Warfield KL, Wells J, Enterlein S, Smith M, Ruthel G, Yunus AS, Kinch MS, Goldblatt M, Aman MJ, Bavari S. Antiviral activity of a small-molecule inhibitor of filovirus infection. Antimicrobial Agents and Chemotherapy. 54: 2152-9. PMID 20211898 DOI: 10.1128/Aac.01315-09  1
2010 Bonavia A, Diaz LS, Santos D, Cassella J, Fesseha Z, Bamba D, Sui B, Li WB, Duan R, Goldblatt M, Kinch MS, Chen LM, Donis RO. Antibody targeting of TSG101 on influenza-infected cells Virus Adaptation and Treatment. 2: 147-157. DOI: 10.2147/Vaat.S13506  1
2009 Kinch MS, Yunus AS, Lear C, Mao H, Chen H, Fesseha Z, Luo G, Nelson EA, Li L, Huang Z, Murray M, Ellis WY, Hensley L, Christopher-Hennings J, Olinger GG, et al. FGI-104: a broad-spectrum small molecule inhibitor of viral infection. American Journal of Translational Research. 1: 87-98. PMID 19966942 DOI: 10.1016/J.Antiviral.2009.02.082  1
2009 Li WB, Zhu J, Hart B, Sui B, Weng K, Chang S, Geiger R, Torremorell M, Mileham A, Gladney C, Mellancamp MA, Li L, Yunus A, Goldblatt M, Kinch MS. Identification of PTCH1 requirement for influenza virus using random homozygous gene perturbation. American Journal of Translational Research. 1: 259-66. PMID 19956436  1
2009 Mao H, Chen H, Fesseha Z, Chang S, Ung-Medoff H, Van Dyke J, Kohli M, Li WB, Goldblatt M, Kinch MS. Identification of novel host-oriented targets for Human Immunodeficiency Virus type 1 using Random Homozygous Gene Perturbation. Virology Journal. 6: 154. PMID 19788744 DOI: 10.1186/1743-422X-6-154  1
2009 Aman MJ, Kinch MS, Warfield K, Warren T, Yunus A, Enterlein S, Stavale E, Wang P, Chang S, Tang Q, Porter K, Goldblatt M, Bavari S. Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Research. 83: 245-51. PMID 19523489 DOI: 10.1016/J.Antiviral.2009.06.001  1
2009 Kinch MS, Kohli M, Goldblatt M, Li WB. Function-first approaches to improve target identification in cancer. Future Oncology (London, England). 5: 617-23. PMID 19519202 DOI: 10.2217/Fon.09.42  1
2009 Bruckheimer EM, Fazenbaker CA, Gallagher S, Mulgrew K, Fuhrmann S, Coffman KT, Walsh W, Ready S, Cook K, Damschroder M, Kinch M, Kiener PA, Woods R, Gao C, Dall'Acqua W, et al. Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors. Neoplasia (New York, N.Y.). 11: 509-17, 2 p followin. PMID 19484140 DOI: 10.1593/Neo.81578  1
2009 Sui B, Bamba D, Weng K, Ung H, Chang S, Van Dyke J, Goldblatt M, Duan R, Kinch MS, Li WB. The use of Random Homozygous Gene Perturbation to identify novel host-oriented targets for influenza. Virology. 387: 473-81. PMID 19327807 DOI: 10.1016/J.Virol.2009.02.046  1
2009 Yunus A, Warren T, Warfield K, Enterlein S, Chang S, Mao H, Aman J, Bavari S, Goldblatt M, Kinch M. Identification of a Small-molecule Antiviral with Broad-spectrum Application to Multiple, Lethal Virus Types Antiviral Research. 82: A74-A75. DOI: 10.1016/J.Antiviral.2009.02.197  0.01
2009 Diaz L, Cassella J, Bonavia A, Duan R, Santos D, Fesseha Z, Goldblatt M, Kinch M. Recruitment of the TSG101/ESCRT-I Machinery in Host Cells by Influenza Virus: Implications for Broad-Spectrum Therapy Antiviral Research. 82: A71. DOI: 10.1016/J.Antiviral.2009.02.175  0.01
2008 Wesa AK, Herrem CJ, Mandic M, Taylor JL, Vasquez C, Kawabe M, Tatsumi T, Leibowitz MS, Finke JH, Bukowski RM, Bruckheimer E, Kinch MS, Storkus WJ. Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists. Journal of Immunology (Baltimore, Md. : 1950). 181: 7721-7. PMID 19017961 DOI: 10.4049/Jimmunol.181.11.7721  1
2008 Jackson D, Gooya J, Mao S, Kinneer K, Xu L, Camara M, Fazenbaker C, Fleming R, Swamynathan S, Meyer D, Senter PD, Gao C, Wu H, Kinch M, Coats S, et al. A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Research. 68: 9367-74. PMID 19010911 DOI: 10.1158/0008-5472.Can-08-1933  1
2008 Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY, Spannuth WA, Nick AM, Jennnings NB, Kinch MS, Tice D, Sood AK. Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia (New York, N.Y.). 10: 1259-67. PMID 18953435 DOI: 10.1593/Neo.08740  1
2008 Lu C, Shahzad MM, Wang H, Landen CN, Kim SW, Allen J, Nick AM, Jennings N, Kinch MS, Bar-Eli M, Sood AK. EphA2 overexpression promotes ovarian cancer growth. Cancer Biology & Therapy. 7: 1098-103. PMID 18443431 DOI: 10.4161/Cbt.7.7.6168  1
2007 Hammond SA, Lutterbuese R, Roff S, Lutterbuese P, Schlereth B, Bruckheimer E, Kinch MS, Coats S, Baeuerle PA, Kufer P, Kiener PA. Selective targeting and potent control of tumor growth using an EphA2/CD3-bispecific single-chain antibody construct Cancer Research. 67: 3927-3935. PMID 17440108 DOI: 10.1158/0008-5472.Can-06-2760  1
2007 Lin YG, Han LY, Kamat AA, Merritt WM, Landen CN, Deavers MT, Fletcher MS, Urbauer DL, Kinch MS, Sood AK. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer. 109: 332-40. PMID 17154180 DOI: 10.1002/Cncr.22415  1
2006 Mulgrew K, Kinneer K, Yao XT, Ward BK, Damschroder MM, Walsh B, Mao SY, Gao C, Kiener PA, Coats S, Kinch MS, Tice DA. Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin. Molecular Cancer Therapeutics. 5: 3122-9. PMID 17172415 DOI: 10.1158/1535-7163.Mct-06-0356  1
2006 Landen CN, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, ... ... Kinch MS, et al. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. Journal of the National Cancer Institute. 98: 1558-70. PMID 17077358 DOI: 10.1093/Jnci/Djj414  1
2006 Merritt WM, Thaker PH, Landen CN, Deavers MT, Fletcher MS, Lin YG, Han LY, Kamat AA, Schmandt R, Gershenson DM, Kinch MS, Sood AK. Analysis of EphA2 expression and mutant p53 in ovarian carcinoma. Cancer Biology & Therapy. 5: 1357-60. PMID 16969087 DOI: 10.4161/Cbt.5.10.3225  1
2006 Hess AR, Seftor EA, Gruman LM, Kinch MS, Seftor RE, Hendrix MJ. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biology & Therapy. 5: 228-33. PMID 16481735 DOI: 10.4161/Cbt.5.2.2510  1
2006 Abraham S, Knapp DW, Cheng L, Snyder PW, Mittal SK, Bangari DS, Kinch M, Wu L, Dhariwal J, Mohammed SI. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder Clinical Cancer Research. 12: 353-360. PMID 16428472 DOI: 10.1158/1078-0432.Ccr-05-1505  1
2006 Zabell KM, Laurence JS, Kinch MS, Knapp DW, Stauffacher CV. Expression and purification of the intact cytoplasmic domain of the human ephrin receptor A2 tyrosine kinase in Escherichia coli. Protein Expression and Purification. 47: 210-6. PMID 16426859 DOI: 10.1016/J.Pep.2005.10.031  1
2006 Hammond SA, Fuhrmann S, Roff S, Kiener PA, Coats S, Kinch MS. Mechanistic Evaluation of Siplizumab (MEDI-507) Activity on Normal and Malignant T-Lymphocytes. Blood. 108: 2504-2504. DOI: 10.1182/Blood.V108.11.2504.2504  0.01
2005 Landen CN, Kinch MS, Sood AK. EphA2 as a target for ovarian cancer therapy. Expert Opinion On Therapeutic Targets. 9: 1179-87. PMID 16300469 DOI: 10.1517/14728222.9.6.1179  1
2005 Hatano M, Eguchi J, Tatsumi T, Kuwashima N, Dusak JE, Kinch MS, Pollack IF, Hamilton RL, Storkus WJ, Okada H. EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia (New York, N.Y.). 7: 717-22. PMID 16207473 DOI: 10.1593/Neo.05277  1
2005 Herrem CJ, Tatsumi T, Olson KS, Shirai K, Finke JH, Bukowski RM, Zhou M, Richmond AL, Derweesh I, Kinch MS, Storkus WJ. Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 226-31. PMID 15671550  1
2004 Hu M, Carles-Kinch KL, Zelinski DP, Kinch MS. EphA2 induction of fibronectin creates a permissive microenvironment for malignant cells. Molecular Cancer Research : McR. 2: 533-40. PMID 15498927  1
2004 Noblitt LW, Bangari DS, Shukla S, Knapp DW, Mohammed S, Kinch MS, Mittal SK. Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Cancer Gene Therapy. 11: 757-66. PMID 15359289 DOI: 10.1038/Sj.Cgt.7700761  1
2004 Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, Kinch MS, Kiener PA, Sood AK. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 5145-50. PMID 15297418 DOI: 10.1158/1078-0432.Ccr-03-0589  1
2004 Cheng L, Pan CX, Zhang JT, Zhang S, Kinch MS, Li L, Baldridge LA, Wade C, Hu Z, Koch MO, Ulbright TM, Eble JN. Loss of 14-3-3sigma in prostate cancer and its precursors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3064-8. PMID 15131044 DOI: 10.1158/1078-0432.Ccr-03-0652  1
2004 Pan CX, Kinch MS, Kiener PA, Langermann S, Serrero G, Sun L, Corvera J, Sweeney CJ, Li L, Zhang S, Baldridge LA, Jones TD, Koch MO, Ulbright TM, Eble JN, et al. PC cell-derived growth factor expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 1333-7. PMID 14977833 DOI: 10.1158/1078-0432.Ccr-1123-03  1
2003 Pratt RL, Kinch MS. Ligand binding up-regulates EphA2 messenger RNA through the mitogen-activated protein/extracellular signal-regulated kinase pathway. Molecular Cancer Research : McR. 1: 1070-6. PMID 14707290  1
2003 Fedor-Chaiken M, Hein PW, Stewart JC, Brackenbury R, Kinch MS. E-cadherin binding modulates EGF receptor activation. Cell Communication & Adhesion. 10: 105-18. PMID 14681060 DOI: 10.1080/Cac.  1
2003 Coffman KT, Hu M, Carles-Kinch K, Tice D, Donacki N, Munyon K, Kifle G, Woods R, Langermann S, Kiener PA, Kinch MS. Differential EphA2 epitope display on normal versus malignant cells. Cancer Research. 63: 7907-12. PMID 14633720  1
2003 Zeng G, Hu Z, Kinch MS, Pan CX, Flockhart DA, Kao C, Gardner TA, Zhang S, Li L, Baldridge LA, Koch MO, Ulbright TM, Eble JN, Cheng L. High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. The American Journal of Pathology. 163: 2271-6. PMID 14633601 DOI: 10.1016/S0002-9440(10)63584-5  1
2003 Irvin BJ, Wood LD, Wang L, Fenrick R, Sansam CG, Packham G, Kinch M, Yang E, Hiebert SW. TEL, a putative tumor suppressor, induces apoptosis and represses transcription of Bcl-XL. The Journal of Biological Chemistry. 278: 46378-86. PMID 12960174 DOI: 10.1074/Jbc.M305189200  1
2003 Tatsumi T, Herrem CJ, Olson WC, Finke JH, Bukowski RM, Kinch MS, Ranieri E, Storkus WJ. Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma Cancer Research. 63: 4481-4489. PMID 12907621  1
2003 Lu M, Miller KD, Gokmen-Polar Y, Jeng MH, Kinch MS. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. Cancer Research. 63: 3425-9. PMID 12810680  1
2003 Walker-Daniels J, Hess AR, Hendrix MJ, Kinch MS. Differential regulation of EphA2 in normal and malignant cells. The American Journal of Pathology. 162: 1037-42. PMID 12651595 DOI: 10.1016/S0002-9440(10)63899-0  1
2003 Kinch MS, Carles-Kinch K. Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer. Clinical & Experimental Metastasis. 20: 59-68. PMID 12650608 DOI: 10.1023/A:1022546620495  1
2003 Kinch MS, Moore MB, Harpole DH. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 613-8. PMID 12576426  1
2002 Walker-Daniels J, Riese DJ, Kinch MS. c-Cbl-dependent EphA2 protein degradation is induced by ligand binding. Molecular Cancer Research : McR. 1: 79-87. PMID 12496371  1
2002 Pratt RL, Kinch MS. Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade. Oncogene. 21: 7690-9. PMID 12400011 DOI: 10.1038/Sj.Onc.1205758  1
2002 Kikawa KD, Vidale DR, Van Etten RL, Kinch MS. Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation. The Journal of Biological Chemistry. 277: 39274-9. PMID 12167657 DOI: 10.1074/Jbc.M207127200  1
2002 Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Research. 62: 2840-7. PMID 12019162  1
2002 Zelinski DP, Zantek ND, Walker-Daniels J, Peters MA, Taparowsky EJ, Kinch MS. Estrogen and Myc negatively regulate expression of the EphA2 tyrosine kinase. Journal of Cellular Biochemistry. 85: 714-20. PMID 11968011 DOI: 10.1002/Jcb.10186  1
2001 Dodge Zantek N, Walker-Daniels J, Stewart J, Hansen RK, Robinson D, Miao H, Wang B, Kung HJ, Bissell MJ, Kinch MS. MCF-10A-NeoST: A new cell system for studying cell-ECM and cell-cell interactions in breast cancer Clinical Cancer Research. 7: 3640-3648. PMID 11705887  1
2001 D'Amico TA, Aloia TA, Moore MBH, Conlon DH, Herndon JE, Kinch MS, Harpole DH. Predicting the sites of metastases from lung cancer using molecular biologic markers Annals of Thoracic Surgery. 72: 1144-1148. PMID 11603427 DOI: 10.1016/S0003-4975(01)02979-4  1
2001 Hess AR, Seftor EA, Gardner LMG, Carles-Kinch K, Schneider GB, Seftor REB, Kinch MS, Hendrix MJC. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: Role of epithelial cell kinase (Eck/EphA2) Cancer Research. 61: 3250-3255. PMID 11309274  1
2001 Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Research. 61: 2301-6. PMID 11280802  1
2001 Kinch MS. Cytometric analysis of cell contact and adhesion Methods in Cell Biology. 599-612. PMID 11060861 DOI: 10.1016/S0091-679X(01)63032-2  1
2001 Zantek ND, Kinch MS. Analysis of cell migration Methods in Cell Biology. 549-559. PMID 11060858 DOI: 10.1016/S0091-679X(01)63029-2  1
2000 Fenrick R, Wang L, Nip J, Amann JM, Rooney RJ, Walker-Daniels J, Crawford HC, Hulboy DL, Kinch MS, Matrisian LM, Hiebert SW. TEL, a putative tumor suppressor, modulates cell growth and cell morphology of ras-transformed cells while repressing the transcription of stromelysin-1. Molecular and Cellular Biology. 20: 5828-39. PMID 10913166 DOI: 10.1128/Mcb.20.16.5828-5839.2000  1
2000 Miao H, Burnett E, Kinch M, Simon E, Wang B. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation Nature Cell Biology. 2: 62-69. PMID 10655584 DOI: 10.1038/35000008  1
1999 Walker-Daniels J, Coffman K, Azimi M, Rhim JS, Bostwick DG, Snyder P, Kerns BJ, Waters DJ, Kinch MS. Overexpression of the EphA2 tyrosine kinase in prostate cancer. The Prostate. 41: 275-80. PMID 10544301 DOI: 10.1002/(Sici)1097-0045(19991201)41:4<275::Aid-Pros8>3.0.Co;2-T  1
1999 Zantek ND, Azimi M, Fedor-Chaiken M, Wang B, Brackenbury R, Kinch MS. E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 10: 629-38. PMID 10511313  1
1999 Miller LA, Hong JJ, Kinch MS, Harrison ML, Geahlen RL. The engagement of beta1 integrins on promonocytic cells promotes phosphorylation of Syk and formation of a protein complex containing Lyn and beta1 integrin. European Journal of Immunology. 29: 1426-34. PMID 10359096 DOI: 10.1002/(Sici)1521-4141(199905)29:05<1426::Aid-Immu1426>3.0.Co;2-J  1
1998 Kinch MS, Kilpatrick KE, Zhong C. Identification of tyrosine phosphorylated adhesion proteins in human cancer cells Hybridoma. 17: 227-235. PMID 9708824 DOI: 10.1089/Hyb.1998.17.227  1
1998 Stearns ME, Ware JL, Agus DB, Chang CJ, Fidler IJ, Fife RS, Goode R, Holmes E, Kinch MS, Peehl DM, Pretlow TG, Thalmann GN. Workgroup 2: human xenograft models of prostate cancer. The Prostate. 36: 56-8. PMID 9650917 DOI: 10.1002/(Sici)1097-0045(19980615)36:1<56::Aid-Pros10>3.0.Co;2-H  1
1998 Brady-Kalnay SM, Mourton T, Nixon JP, Pietz GE, Kinch M, Chen H, Brackenbury R, Rimm DL, Del Vecchio RL, Tonks NK. Dynamic interaction of PTPmu with multiple cadherins in vivo. The Journal of Cell Biology. 141: 287-96. PMID 9531566 DOI: 10.1083/Jcb.141.1.287  1
1997 O'Brien ET, Kinch M, Harding TW, Epstein DL. A mechanism for trabecular meshwork cell retraction: Ethacrynic acid initiates the dephosphorylation of focal adhesion proteins Experimental Eye Research. 65: 471-483. PMID 9464181 DOI: 10.1006/Exer.1997.0357  1
1997 Zhong C, Kinch MS, Burridge K. Rho-stimulated contractility contributes to the fibroblastic phenotype of Ras-transformed epithelial cells. Molecular Biology of the Cell. 8: 2329-44. PMID 9362072 DOI: 10.1091/Mbc.8.11.2329  1
1997 Kinch MS, Petch L, Zhong C, Burridge K. E-cadherin engagement stimulates tyrosine phosphorylation. Cell Adhesion and Communication. 4: 425-37. PMID 9177904 DOI: 10.3109/15419069709004459  1
1997 Clark GJ, Kinch MS, Rogers-Graham K, Sebti SM, Hamilton AD, Der CJ. The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation Journal of Biological Chemistry. 272: 10608-10615. PMID 9099708 DOI: 10.1074/Jbc.272.16.10608  1
1996 Clark GJ, Kinch MS, Gilmer TM, Burridge K, Der CJ. Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers. Oncogene. 12: 169-76. PMID 8552388  1
1995 Kinch MS, Burridge K. Altered adhesions in ras-transformed breast epithelial cells. Biochemical Society Transactions. 23: 446-50. PMID 8566335 DOI: 10.1042/Bst0230446  1
1995 Khosravi-Far R, Solski PA, Clark GJ, Kinch MS, Der CJ. Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation. Molecular and Cellular Biology. 15: 6443-53. PMID 7565796 DOI: 10.1128/Mcb.15.11.6443  1
1995 Kinch MS, Clark GJ, Der CJ, Burridge K. Tyrosine phosphorylation regulates the adhesions of ras-transformed breast epithelia. The Journal of Cell Biology. 130: 461-71. PMID 7542250 DOI: 10.1083/Jcb.130.2.461  1
1994 Kinch MS, Sanfridson A, Doyle C. The protein tyrosine kinase p56lck regulates cell adhesion mediated by CD4 and major histocompatibility complex class II proteins Journal of Experimental Medicine. 180: 1729-1739. PMID 7964457 DOI: 10.1084/Jem.180.5.1729  1
1994 Chen Q, Kinch MS, Lin TH, Burridge K, Juliano RL. Integrin-mediated cell adhesion activates mitogen-activated protein kinases Journal of Biological Chemistry. 269: 26602-26605. PMID 7929388  1
1993 Kirk AD, Li RA, Kinch MS, Abernethy KA, Doyle C, Bollinger RR. The human antiporcine cellular repertoire: In vitro studies of acquired and innate cellular responsiveness Transplantation. 55: 924-931. PMID 8475569 DOI: 10.1097/00007890-199304000-00043  1
1993 Kinch MS, Strominger JL, Doyle C. Cell adhesion mediated by CD4 and MHC class II proteins requires active cellular processes Journal of Immunology. 151: 4552-4561. PMID 8104997  1
1993 Vignali DA, Doyle C, Kinch MS, Shin J, Strominger JL. Interactions of CD4 with MHC class II molecules, T cell receptors and p56lck Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences. 342: 13-24. PMID 7506833 DOI: 10.1098/Rstb.1993.0130  1
1993 KIRK AD, LI RA, KINCH MS, ABERNETHY KA, DOYLE C, BOLLINGER RR. THE HUMAN ANTIPORCINE CELLULAR REPERTOIRE Transplantation. 55: 924-931. DOI: 10.1097/00007890-199304000-00043  0.01
Show low-probability matches.